Investor Relations

NEW YORK , Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

NEW YORK , Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ,  a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune cell therapy